Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
67%
Ph phase_3
2
33%

Phase Distribution

4

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 32 (33.3%)

Trials by Status

active_not_recruiting117%
completed350%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_3

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
completedphase_1

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

NCT04154488
active_not_recruitingphase_3

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03995108
completedphase_1

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869
recruitingphase_1

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06056297Phase 3

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Recruiting
NCT04154488Phase 1

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
NCT03995108Phase 3

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Active Not Recruiting
NCT06914869Phase 1

Drug-Drug Interaction Potential of Mavorixafor

Completed
NCT06858696Phase 1

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Recruiting
NCT04274738Phase 1

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6